Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis: Post hoc analysis of a large phase 3 trial

[1]  Jennifer A. Villwock,et al.  International consensus statement on allergy and rhinology: Allergic rhinitis – 2023 , 2023, International forum of allergy & rhinology.

[2]  R. Pawankar,et al.  Is "Maintenance" a Misnomer? A Narrative Framework Setting the Right Expectations of Allergen Immunotherapy. , 2023, The journal of allergy and clinical immunology. In practice.

[3]  K. Bergmann,et al.  Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet , 2023, Allergo Journal International.

[4]  M. Wagenmann,et al.  Guideline on allergen immunotherapy in IgE-mediated allergic diseases , 2022, Allergologie select.

[5]  Todor A Popov,et al.  ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy , 2021, Clinical and translational allergy.

[6]  G. Canonica,et al.  One Hundred Ten Years of Allergen Immunotherapy: A Broad Look Into the Future. , 2021, The journal of allergy and clinical immunology. In practice.

[7]  D. Ryan,et al.  EUFOREA treatment algorithm for allergic rhinitis , 2020, Rhinology journal.

[8]  T. Casale,et al.  A 300°IR sublingual tablet is an effective, safe treatment for house-dust-mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized Phase III clinical trial. , 2020, The Journal of allergy and clinical immunology.

[9]  J. Bousquet,et al.  Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs , 2020, Clinical and Translational Allergy.

[10]  S. Lutfeali,et al.  Efficacy of House Dust Mite Sublingual Tablet in the Treatment of Allergic Rhinoconjunctivitis: A Randomized Trial in a Pediatric Population , 2019, Pediatrics.

[11]  V. Backer,et al.  SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis , 2019, Expert review of clinical immunology.

[12]  Y. Okamoto,et al.  Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population , 2018, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[13]  A. Sheikh,et al.  EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis , 2018, Allergy.

[14]  P. Demoly,et al.  Allergic rhinitis increases the risk of driving accidents. , 2017, The Journal of allergy and clinical immunology.

[15]  T. Casale,et al.  Allergen Immunotherapy Clinical Trial Outcomes and Design: Working Toward Harmonization of Methods and Principles , 2017, Current Allergy and Asthma Reports.

[16]  William H. Yang,et al.  300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis , 2016, Expert review of clinical immunology.

[17]  Y. Okamoto,et al.  House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis , 2016, Allergy.

[18]  William H. Yang,et al.  Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. , 2016, The Journal of allergy and clinical immunology.

[19]  J. Virchow,et al.  Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma , 2016, Expert review of clinical immunology.

[20]  P. Demoly,et al.  SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis , 2016, Expert review of clinical immunology.

[21]  V. Backer,et al.  Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. , 2016, The Journal of allergy and clinical immunology.

[22]  P. Demoly,et al.  International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. , 2016, The Journal of allergy and clinical immunology.

[23]  J. Virchow,et al.  House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies. , 2015, The journal of allergy and clinical immunology. In practice.

[24]  Allan Linneberg,et al.  Respiratory allergy caused by house dust mites: What do we really know? , 2015, The Journal of allergy and clinical immunology.

[25]  R. Gerth van Wijk,et al.  Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials? , 2015, Current Treatment Options in Allergy.

[26]  R. Bush,et al.  Immunotherapy for House Dust Mite Sensitivity: Where Are the Knowledge Gaps? , 2014, Current Allergy and Asthma Reports.

[27]  K. Lyseng-Williamson.  Standardized sublingual allergen extract solution (Staloral®): a guide to its use as allergen-specific immunotherapy , 2014 .

[28]  J. Bousquet,et al.  Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. , 2014, Allergy.

[29]  F. Chew,et al.  Allergic airway diseases in a tropical urban environment are driven by dominant mono-specific sensitization against house dust mites , 2014, Allergy.

[30]  M. Asaduzzaman,et al.  House Dust Mite Interactions with Airway Epithelium: Role in Allergic Airway Inflammation , 2013, Current Allergy and Asthma Reports.

[31]  P. Howarth,et al.  How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement , 2011, Allergy.

[32]  Holger J Schünemann,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.

[33]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[34]  J Bousquet,et al.  Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce , 2007, Allergy.

[35]  R. Settipane,et al.  Allergic rhinitis , 2005, Rhinology and Anterior Skull Base Surgery.

[36]  P. V. Cauwenberge,et al.  Allergic rhinitis and its impact on asthma. , 2001, The Journal of allergy and clinical immunology.

[37]  P. Demoly,et al.  Rhinitis , sinusitis , and upper airway disease Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis , 2016 .

[38]  ON IN VITRO INVESTIGATION OF MITOCHONDRIAL TOXICITY OF ANTI-HIV NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS , 2008 .

[39]  P. Cauwenberge.  Allergic Rhinitis and its Impact on Asthma (ARIA) , 2002 .